Nasipral (Ipratropium Bromide)

Ipratropium bromide, the active ingredient in Nasipral, is an anticholinergic (muscarinic antagonist) presented as a nasal spray for nasal use. It relieves nasal congestion by reducing secretions and vasodilation in the nasal mucosa. Nasipral is marketed in the European Union and is intended for short‑term symptomatic relief of nasal blockage.

GNH USA supplies Nasipral as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nasipral, an anticholinergic nasal spray, is employed to manage conditions that cause nasal blockage.

Nasal congestion: reduces swelling and mucus production to improve airflow. Allergic rhinitis: alleviates congestion associated with seasonal allergies. Common cold: provides symptomatic relief of nasal blockage during viral upper respiratory infections.

Nasipral may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dry nose - Throat irritation - Cough - Altered taste sensation - Headache - Nasal discomfort

Serious or Rare Side Effects: - Allergic reaction (rash, swelling, anaphylaxis) - Bronchospasm - Severe nasal bleeding - Paradoxical worsening of congestion - Vision changes - Acute angle‑closure glaucoma

Before using Nasipral, consider the following safety measures.

Pregnancy: consult a healthcare professional before use. Breastfeeding: discuss potential risks with a physician. Elderly: monitor for heightened anticholinergic effects. Concurrent respiratory disease: use with caution. Hypersensitivity: avoid if known allergy to ipratropium or atropine derivatives. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nasipral can interact with other medications; awareness of the interaction level is important.

Major Interactions (Avoid): - Concurrent use of other anticholinergic nasal sprays: may increase anticholinergic load. - Beta‑agonist inhalers: additive bronchodilator effect may cause tachycardia.

Moderate Interactions (Monitor Closely): - Oral antihistamines: may enhance nasal dryness. - MAO inhibitors: monitor for increased anticholinergic side effects. - Other nasal decongestants: risk of additive irritation.